Catalent Pharma Solutions and BASF have entered into a broad collaboration and Open Alliance to provide solutions to overcome bioavailability challenges of new molecular entities with solubility or permeability challenges.
The companies aim to provide pharmaceutical customers with solutions to address pipeline challenges with a large majority of BCS Class II and IV poorly bioavailable compounds.
From feasibility studies across multiple technologies, solid state chemistry, consulting and training, expert formulation services, excipients and optimal dose form development, to scale-up and supply, BASF and Catalent provide a full solution to one of the most important pipeline challenges in the industry - getting better treatments to market faster.
